Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2021 Sep 30;22(1):257.
doi: 10.1186/s12931-021-01851-4.

Hospitalizations in patients with idiopathic pulmonary fibrosis

Hyun J Kim  1 , Laurie D Snyder  2   3 , Ayodeji Adegunsoye  4 , Megan L Neely  2   3 , Shaun Bender  5 , Eric S White  5 , Craig S Conoscenti  5 , Mary E Strek  4 ; IPF-PRO Registry Investigators
Collaborators, Affiliations
Observational Study

Hospitalizations in patients with idiopathic pulmonary fibrosis

Hyun J Kim et al. Respir Res. .

Abstract

Background: Hospitalizations are common among patients with idiopathic pulmonary fibrosis (IPF). We investigated the impact of hospitalizations on outcomes in patients with IPF.

Methods: The IPF-PRO Registry is an observational US registry that enrolled patients with IPF that was diagnosed or confirmed at the enrolling center in the previous 6 months. Associations between patient characteristics and hospitalization, and between hospitalization and mortality, were analyzed using Cox regression models.

Results: A total of 1002 patients with IPF were enrolled into the IPF-PRO Registry. Over a median follow-up time of 23.7 months (maximum: 67.0 months), 568 patients (56.7%) had at least one hospitalization. Of these patients, 319 (56.2%) had at least one respiratory-related hospitalization and 120 (21.1%) had at least one hospitalization with ventilatory support. Younger age (HR 0.68 [95% CI 0.55, 0.84] per 5-year increase for patients < 62 years), lower BMI (0.96 [0.93, 0.98] per 1-point increase), lower FVC % predicted (0.90 [0.83, 0.97] per 10% increase), oxygen use at rest (2.85 [2.18, 3.72]) and history of pulmonary hypertension (2.02 [1.37, 2.96]) at enrollment were associated with an increased risk of respiratory-related hospitalization during follow-up. In a multivariable model, there was an eightfold increase in the risk of mortality during hospitalization or within 90 days of discharge compared with outside of this period. The risk of mortality associated with a respiratory hospitalization or a hospitalization with ventilatory support was even greater.

Conclusions: Data from the IPF-PRO Registry demonstrate that hospitalizations are common among patients with IPF. The risk of mortality during hospitalization or within 90 days of discharge was high, particularly among patients who were hospitalized for a respiratory cause or received ventilatory support. Trial registration ClinicalTrials.gov, NCT01915511. Registered 5 August 2013, https://clinicaltrials.gov/ct2/show/NCT01915511.

Keywords: Interstitial lung disease; Mechanical ventilation; Mortality; Pulmonary fibrosis; Respiratory function tests.

PubMed Disclaimer

Conflict of interest statement

HJK is a member of the Publication Committee for the IPF-PRO/ILD-PRO Registry. LDS and MLN are faculty members in the Duke Clinical Research Institute (DCRI), which receives funding support from Boehringer Ingelheim Pharmaceuticals, Inc to co-ordinate the IPF-PRO/ILD-PRO Registry. AA reports grants and personal fees from Boehringer Ingelheim, personal fees from Genentech and grants from the Pulmonary Fibrosis Foundation and the National Institutes of Health. SB, ESW and CSC are employees of Boehringer Ingelheim Pharmaceuticals, Inc. MES reports grants, personal fees and non-financial support from Boehringer Ingelheim; grants from Galapagos; and personal fees from FibroGen.

Figures

Fig. 1
Fig. 1
Associations between hospitalization and mortality
See this image and copyright information in PMC

References

    1. Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198(5):e44–e68. doi: 10.1164/rccm.201807-1255ST. - DOI - PubMed
    1. Durheim MT, Collard HR, Roberts RS, et al. Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials. Lancet Respir Med. 2015;3(5):388–396. doi: 10.1016/S2213-2600(15)00093-4. - DOI - PMC - PubMed
    1. Mooney JJ, Raimundo K, Chang E, Broder MS. Mechanical ventilation in idiopathic pulmonary fibrosis: a nationwide analysis of ventilator use, outcomes, and resource burden. BMC Pulm Med. 2017;17(1):84. doi: 10.1186/s12890-017-0426-2. - DOI - PMC - PubMed
    1. Durheim MT, Judy J, Bender S, et al. In-hospital mortality in patients with idiopathic pulmonary fibrosis: a US cohort study. Lung. 2019;197(6):699–707. doi: 10.1007/s00408-019-00270-z. - DOI - PMC - PubMed
    1. Durheim MT, Judy J, Bender S, et al. A retrospective study of in-hospital mortality in patients with idiopathic pulmonary fibrosis between 2015 and 2018. Medicine (Baltimore) 2020;99(47):e23143. doi: 10.1097/MD.0000000000023143. - DOI - PMC - PubMed

Publication types

Associated data